FDA
-
-
-
-
-
-
-
Avidity Biosciences delays del-zota filing to Q1 2026 after FDA meeting
-
-
-
-
-
-
-
Why public perception matters so much for biotech valuations
-
-
-
-
-
-
-
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE⢠Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Researc
-
-
-
-
-
-
-
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights
-
-
-
-
-
-
-
BMO Capital Starts Avidity Biosciences (RNA) at Outperform (correction)
-
-
-
-
-
-
-
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
-
-
-
-
-
-
-
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

